Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Circassia Group PLC - Oxford, England-based medical device focused on point-of-care asthma diagnosis and management - Posts higher revenue in the first four months of 2022 than Circassia management had expected. Clinical revenue is up 17% compared to the same period in 2021. Research revenue also is slightly up, firm adds. Lockdowns may affect the business in China, but trading so far is strong with growth of over 23% there compared to a year ago.
Circassia expects its earnings before interest, tax, depreciation and amortisation for the full year to be ‘materially ahead of its expectations’, based on a strong performance in the year to date. Regarding managing asthma, the firm is ‘seeking to address the home-use market with a simplified device’, Executive Chair Ian Johnson says.
Current stock price: 37.50 pence, up 13% on Thursday
12-month change: up 15%
Copyright 2022 Alliance News Limited. All Rights Reserved.